A new study, yet to receive any media attention, reveals the “leukemogenic” properties of the Bt toxin biopesticides engineered into the vast majority of GMO food crops already within the US food supply.
Last September, the causal link between cancer and genetically modified food was confirmed in a French study, the first independent long-term animal feeding study of its kind. The disturbing details can be found here: New Study Finds GM Corn and Roundup Causes Cancer In Rats
Now, a new study published in the Journal of Hematology & Thromboembolic Diseases indicates that the biopesticides engineered into GM crops known as Bacillus Thuringensis (Bt) or Cry-toxins, may also contribute to blood abnormalities from anemia to hematological malignancies (blood cancers) such as leukemia.[i]
A group of scientists from the Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brasilia/DF, Brazil set out to test the purported human and environmental biosafety of GM crops, looking particularly at the role that the Bt toxin found within virtually all GM food crops plays on non-target or non-insect animal species.
The research was spurned by the Brazilian Collegiate Board of Directors of the National Sanitary Surveillance Agency (ANVISA), who advocated in 2005 for evaluations of toxicity and pathogenicity of microbiological control agents such as Bt, given that little is known about their toxicological potential in non-target organisms, including humans.
The researchers also found that one of the prevailing myths about the selective toxicity of Bt to insects, the target species, no longer holds true:
It has been reported that Cry toxins exert their toxicity when activated at alkaline pH of the digestive tract of susceptible larvae, and, because the physiology of the mammalian digestive system does not allow their activation, and no known specific receptors in mammalian intestinal cells have been reported, the toxicity these MCAs to mammals would negligible [8,22,23]. However, our study demonstrated that Bt spore-crystals genetically modified to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A induced hematotoxicity, particularly to the erythroid lineage. This finding corroborates literature that demonstrated that alkali-solubilized Bt spore-crystals caused in vitro hemolysis in cell lines of rat, mouse, sheep, horse, and human erythrocytes and suggested that the plasma membrane of susceptible cells (erythrocytes, in this case) may be the primary target for these toxins 
The study also found:
1) That Cry toxins are capable of exerting their adverse effects when suspended in distilled water, not requiring alkalinization via insect physiology to become activated as formerly believed.
2) That a dose of Cry1Ab as low as 27 mg/kg, their lowest tested dose, was capable of inducing hypochromic anemia in mice – the very toxin has been detected in blood of non-pregnant women, pregnant women and their fetuses in Canada, supposedly exposed through diet.
3) Whereas past reports have found that Bt toxins are generally nontoxic and do not bioaccumulate in fatty tissue or persist in the environment, the new study demonstrated that all Cry toxins tested had a more pronounced effect from 72 hours of exposure onwards, indicating the opposite is true.
4) That high-dose Cry toxin doses caused blood changes indicative of bone marrow damage (damage to “hematopoietic stem cell or bone marrow stroma”).
The authors noted their results “demonstrate leukemogenic activity for other spore-crystals not yet reported in the literature.”
[R]esults showed that the Bt spore-crystals genetically modified to express individually Cry1Aa, Cry1Ab, Cry1Ac or Cry2A can cause some hematological risks to vertebrates,increasing their toxic effects with long-term exposure. Taking into account the increased risk of human and animal exposures to significant levels of these toxins, especially through diet, our results suggest that further studies are required to clarify the mechanism involved in the hematotoxicity found in mice, and to establish the toxicological risks to non-target organisms, especially mammals, before concluding that these microbiological control agents are safe for mammals.
Did you get that? Their conclusion is that it is premature to consider GM toxins to be safe in mammals. Billions have already been exposed to Bt toxins, in combination with glyphosate-based herbicide formulations such as Roundup, and yet, most biotech research scientists and industry regulators still claim they are unequivocally safe. This has much to do with the well-known relationship that biotech corporations like Monsanto have with so-called ‘check book’ science firms who are basically paid to obfuscate adverse health outcomes of their products, such as the GMO-Cancer link. [also see: Monsanto-Funded Science Denies Emerging Roundup Cancer Link]
Consider also that the question of combined toxicity of Cry toxins and glyphosate-based residues within plants have not been sufficiently explored, and that glyphosate exposure has already been linked to non-Hodgkins lymphoma and hairy cell leukemia in the biomedical literature.[ii]
The reality is that we no longer have time to wait around for additional research to accumulate on the adverse health effects of GMOs, especially considering the biotech industry has far more capital to infuse into their own faux research on the topic.
daily alternative | alternative news – New Study Links GMO Food To Leukemia
Google Now Has Access To Millions of Patients’ Medical Records
A controversial deal between tech giant Google and the National Health Service (NHS) will allow artificial intelligence units access to 1.6 million confidential medical records. Since 2014, Google has partnered with several scientists in an attempt to understand human health, but a new report reveals the data gathering goes far beyond what was originally anticipated.
According to documents obtained by the New Scientist, the data sharing agreement between Google-owned artificial intelligence company DeepMind and the Royal Free NHS Trust gives access to the sensitive healthcare data of millions of NHS patients. The chilling and wide-reaching deal allows DeepMind access to the medical records of the 1.6 million people passing annually through the three London hospitals owned by the Trust — Barnet, Chase Farm, and the Royal Free.
The Google-owned A.I. firm announced in February it was working with the NHS to build an app called Streams — intended to help hospitals monitor patients with kidney disease. However, the new information has revealed that the extent of the data being shared goes much further and includes logs of day-to-day hospital activity, records of the location and status of patients, and even logs of who visits them and when.
Results of pathology and radiology tests are also shared, as is information from critical care and accident and emergency departments. In addition, DeepMind’s access to the centralised records of all NHS hospital treatments in the U.K. means the tech company can access historical data from the last five years, all while receiving a continuous stream of new data.
At the same time, DeepMind is developing a platform called Patient Rescue, which uses hospital data streams to build tools to carry out analysis and support diagnostic decisions. The New Scientist explained how it works:
Comparing a new patient’s information with millions of other cases, Patient Rescue might be able to predict that they are in the early stages of a disease that has not yet become symptomatic, for example. Doctors could then run tests to see if the prediction is correct.
While the Royal Free has not yet responded to the question of what — if any — opt-out mechanisms are available to patients, the New Scientist suggests this is unlikely to be a straightforward process. Despite the agreement stating Google cannot use the data in any other part of the company’s business, many will be seriously wary of the access the online tech giant now has to the confidential data of millions of people.
As the New Scientist wrote:
Data mining is the name of the game in the burgeoning field of machine learning and artificial intelligence, and there’s no company in the world better at that than Google.
daily alternative | alternative news – Google Now Has Access To Millions of Patients’ Medical Records
Latest Crypto Price
|Quotes delayed up to 3 minutes.|